Raida M, Kliche K-O, Schwabe W, Häusler P, Clement J H, Behnke D, Höffken K
Klinik und Poliklinik für Innere Medizin II, (Onkologie, Hämatologie, Endokrinologie und Stofwechselerkrankungen), Friedrich-Schiller-Universität Jena, Germany.
J Cancer Res Clin Oncol. 2002 Feb;128(2):96-102. doi: 10.1007/s00432-001-0309-y. Epub 2001 Nov 30.
The activity of dihydropyrimidine dehydrogenase (DPD) - the rate-limiting enzyme in fluorouracil (5-FU) catabolism - has been reported to vary according to the time of day. On the basis of this data, so-called chronomodulated chemotherapy regimens with variable-rate infusions of 5-FU have been investigated in the treatment of advanced colorectal cancer. Recent results suggest lower toxicity of 5-FU by chronomodulated application. However, the pattern of circadian DPD activity levels have been shown to vary considerably.
We, therefore, studied the circadian changes in mRNA expression of DPD in leukocytes of ten patients with advanced gastrointestinal carcinomas prior to chronomodulated 5-FU-based salvage therapy and in 5five healthy controls. Simultaneously, we measured serum cortisol levels (SCL) to evaluate the endogenous circadian hormone rhythm.
SCL displayed a consistent circadian rhythm with the mean peak value of serum cortisol at 8 a.m. and the mean trough value at 11 p.m. both in patients and in controls. However, mean minimum-maximum serum cortisol differences of SCL were significantly lower in patients compared to controls. In the 5fivehealthy controls, a trend towards a circadian rhythm of DPD mRNA expression was observed with the peak of expression at 5 a.m. which was significantly different from the trough at 2 p.m. ( P<0.005 Mann-Whitney-Wilcoxon test). When each control was studied separately, only two individuals showed circadian variations that could be fitted to a cosine wave ( P=0.001, P=0.014, Cosinor analysis). In contrast, DPD mRNA expression in patients with advanced gastrointestinal carcinomas did not demonstrate any consistent circadian rhythm. Pairwise comparisons of groups of DPD mRNA levels at different times of the day did not show significant differences.
In conclusion, our analysis of DPD mRNA expression in leukocytes from healthy controls demonstrates first evidence for a circadian DPD mRNA expression periodicity. In patients with advanced gastrointestinal carcinomas, however, this rhythm seems to be disturbed although circadian endogenous cortisol secretion pattern is maintained.
二氢嘧啶脱氢酶(DPD)是氟尿嘧啶(5-FU)分解代谢中的限速酶,据报道其活性会随一天中的时间而变化。基于这些数据,已对采用5-FU可变速率输注的所谓时辰调节化疗方案治疗晚期结直肠癌进行了研究。近期结果表明时辰调节应用5-FU毒性较低。然而,昼夜DPD活性水平模式已显示出有很大差异。
因此,我们研究了10例晚期胃肠道癌患者在基于5-FU的时辰调节挽救治疗前以及5名健康对照者白细胞中DPD mRNA表达的昼夜变化。同时,我们测量了血清皮质醇水平(SCL)以评估内源性昼夜激素节律。
患者和对照者的SCL均呈现出一致的昼夜节律,血清皮质醇的平均峰值出现在上午8点,平均谷值出现在晚上11点。然而,患者的SCL平均最小-最大血清皮质醇差异显著低于对照者。在5名健康对照者中,观察到DPD mRNA表达有昼夜节律的趋势,表达峰值出现在凌晨5点,与下午2点的谷值有显著差异(曼-惠特尼-威尔科克森检验,P<0.005)。当分别研究每个对照者时,只有两人显示出可拟合为余弦波的昼夜变化(余弦分析,P=0.001,P=0.014)。相比之下,晚期胃肠道癌患者的DPD mRNA表达未显示出任何一致的昼夜节律。一天中不同时间的DPD mRNA水平组间两两比较未显示出显著差异。
总之,我们对健康对照者白细胞中DPD mRNA表达的分析首次证明了DPD mRNA表达的昼夜周期性。然而,在晚期胃肠道癌患者中,尽管维持了昼夜内源性皮质醇分泌模式,但这种节律似乎受到了干扰。